In recent trading, shares of Amgen Inc. (AMGN) surpassed the average 12-month analyst target price of $242.67, reaching $243.12 per share. Analysts typically react to such milestones by either downgrading their valuation or raising their price targets. Currently, there are 15 analysts covering Amgen with target prices ranging from $194 to $286, and a standard deviation of $28.704.
The breakdown of analyst ratings shows 4 strong buy ratings, 12 hold ratings, and 1 strong sell rating. The average analyst rating stands at 2.65, where 1 indicates a strong buy and 5 indicates a strong sell. With AMGN’s price exceeding the average target, investors are prompted to reassess the company’s value and consider potential investment decisions.
